Junior De La Rosa Martinez
Research Subjects
Junior De La Rosa Martinez has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Adarsh K. Bhan
Department of Cardiology, Advocate Christ Medical Center, Oak Lawn, IL (A.K.B.).
1 shared publication Alexandru B. Chicos
Division of Cardiology, Department of Medicine, Bluhm Cardiovascular Institute, Northwestern Memorial Hospital, Northwestern University, Chicago, IL (A.B.C.).
1 shared publication- Angkawipa Trongtorsak
Department of Cardiovascular Medicine Virginia Commonwealth University Richmond Virginia USA
1 shared publication - Calambur Narasimhan
AIG Hospitals, Hyderabad, India
1 shared publication - Christopher Madias
Tufts Medical Center
1 shared publication David A. Steckman
Division of Cardiology (D.A.S., M.T.), Albany Medical College, NY
1 shared publication
Latest Publications
- Open Access
- 23 September 2026
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 623
Acetylation promotes thyroid hormone receptor ubiquitination and degradation by nuclear proteasomes
- 23 September 2026
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 623
Open AccessAcetylation promotes thyroid hormone receptor ubiquitination and degradation by nuclear proteasomes
- 1 July 2025
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 18 (7) , e013670
Race Comparisons in Patients With Cardiac Sarcoidosis: Insights From the Cardiac Sarcoidosis Consortium
BACKGROUND: Differences in cardiac sarcoidosis between racial groups remain understudied. Therefore, this study aims to explore race differences in patients with cardiac sarcoidosis. METHODS: We analyzed data from the Cardiac Sarcoidosis Consortium, an international registry including over 25 centers. The primary clinical outcome was a composite end point of all-cause mortality, left ventricular assist device implantation, heart transplantation, or implantable cardioverter defibrillator therapy. RESULTS: A total of 619 patients were included in the study (362 White, 193 Black, and 64 other races). Black patients were diagnosed with cardiac sarcoidosis at a younger age (50.5±11.8 versus 53.7±10.5 years old; P =0.010) compared with White patients. Left ventricular ejection fraction was significantly lower in Black patients (44.6±15.4 versus 48.3±14.0; P =0.008). In addition, extracardiac involvement in the lungs (80.3% versus 72.7%; P =0.046), skin (22.8% versus 12.4%; p =0.002), and eyes (13.5% versus 5.5%; P =0.001) was more prevalent in Black patients. Patients had significantly higher rates of hypertension (69.9% versus 50.6%; P P P P P 35% group (24.1% in Black versus 25.9% in White; P =0.72) and the left ventricular ejection fraction ≤35% group (51% versus 42.5%; P =0.35). CONCLUSIONS: Black patients with cardiac sarcoidosis exhibited significantly higher rates of lung, skin, and eye involvement and comorbidities, but had similar cardiac clinical outcomes and all-cause mortality compared with White patients. Nonetheless, ascertainment bias cannot be excluded.
- 1 July 2025
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 18 (7) , e013670
Race Comparisons in Patients With Cardiac Sarcoidosis: Insights From the Cardiac Sarcoidosis Consortium
BACKGROUND: Differences in cardiac sarcoidosis between racial groups remain understudied. Therefore, this study aims to explore race differences in patients with cardiac sarcoidosis. METHODS: We analyzed data from the Cardiac Sarcoidosis Consortium, an international registry including over 25 centers. The primary clinical outcome was a composite end point of all-cause mortality, left ventricular assist device implantation, heart transplantation, or implantable cardioverter defibrillator therapy. RESULTS: A total of 619 patients were included in the study (362 White, 193 Black, and 64 other races). Black patients were diagnosed with cardiac sarcoidosis at a younger age (50.5±11.8 versus 53.7±10.5 years old; P =0.010) compared with White patients. Left ventricular ejection fraction was significantly lower in Black patients (44.6±15.4 versus 48.3±14.0; P =0.008). In addition, extracardiac involvement in the lungs (80.3% versus 72.7%; P =0.046), skin (22.8% versus 12.4%; p =0.002), and eyes (13.5% versus 5.5%; P =0.001) was more prevalent in Black patients. Patients had significantly higher rates of hypertension (69.9% versus 50.6%; P P P P P 35% group (24.1% in Black versus 25.9% in White; P =0.72) and the left ventricular ejection fraction ≤35% group (51% versus 42.5%; P =0.35). CONCLUSIONS: Black patients with cardiac sarcoidosis exhibited significantly higher rates of lung, skin, and eye involvement and comorbidities, but had similar cardiac clinical outcomes and all-cause mortality compared with White patients. Nonetheless, ascertainment bias cannot be excluded.